Skip to search formSkip to main contentSkip to account menu

MEK Inhibitor GDC-0623

Known as: GDC-0623 
An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Structures of BRAF–MEK1–14-3-3 sheds light on drug discovery
In a recent paper published in Nature, Eunyoung Park et al. reported structures of autoinhibited and active BRAF–MEK1–14-33… 
2019
2019
Abstract 2196: Strong anti-tumor activity of MEK inhibitor GDC-0623 and determination of predictive biomarkers
MEK inhibitors emerged as a promising class of anti-cancer agents to inhibit KRAS/RAF driven tumors like melanoma and colorectal… 
2015
2015
The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism*
Background: Activated KRAS-MEK/ERK signaling confers drug resistance. Results: Mutant KRAS up-regulates BCL-XL via STAT3. A MEK… 
2015
2015
Elucidating the Mechanisms of Formation for Two Unusual Cytochrome P450–Mediated Fused Ring Metabolites of GDC-0623, a MAPK/ERK Kinase Inhibitor
Two isomeric metabolites of GDC-0623 [5-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide… 
2014
2014
Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
2013
2013
Abstract B75: A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.
Background: Deregulation of the RAS/RAF/MEK/ERK signaling pathway has been implicated in diverse human tumors. GDC-0623 is an… 
2013
2013
Abstract 2340: Preferential targeting of KRAS mutant or BRAF mutant tumors using MEK inhibitors with distinct mechanisms of action.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC KRAS and BRAF mutant cancers represent an area of… 
2012
2012
502 Preclinical Pharmacokinetics and Efficacy Assessment of a Potent and Selective MEK Inhibitor, GDC-0623
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)